Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sees Large Decrease in Short Interest

Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 2,440,000 shares, a decrease of 17.3% from the October 31st total of 2,950,000 shares. Based on an average trading volume of 562,900 shares, the days-to-cover ratio is presently 4.3 days.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $17.50.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares during the period. SG Americas Securities LLC acquired a new position in Voyager Therapeutics during the second quarter valued at approximately $85,000. Intech Investment Management LLC bought a new stake in Voyager Therapeutics in the third quarter valued at approximately $74,000. Victory Capital Management Inc. raised its holdings in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC bought a new position in shares of Voyager Therapeutics during the second quarter worth $128,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

VYGR opened at $6.86 on Friday. The firm has a 50 day simple moving average of $6.51 and a 200 day simple moving average of $7.31. Voyager Therapeutics has a fifty-two week low of $5.19 and a fifty-two week high of $11.72. The company has a market cap of $374.73 million, a price-to-earnings ratio of 9.66 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the previous year, the company posted ($0.59) EPS. As a group, analysts expect that Voyager Therapeutics will post -1.03 EPS for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.